5-MeO-DMT
5-methoxy-N,N-dimethyltryptamine
Viewing r1 — Apr 24, 2026 — CURRENT
Back to HistoryInteractions, related substances, and reports reflect the current entry and are not shown for historical revisions.
5-MeO-DMT (5-methoxy-N,N-dimethyltryptamine) is a naturally-occurring psychedelic of the tryptamine class. It is the 5-methoxy structural analog of DMT, distinguished by extreme potency and ultra-short duration. 5-MeO-DMT is a 5-HT₂A receptor agonist, producing its effects through serotonin receptor activation modulated by concurrent 5-HT₁A stimulation.[1]
Psychedex is in open beta. We are still fine-tuning the generation and review process. Please double-check sources.
DMT, psilocybin, LSD +1 moreDMT, psilocybin, LSD, mescaline show less
First synthesized in 1936 and later identified in plants and in the parotoid gland secretions of the Sonoran Desert toad (Incilius alvarius), 5-MeO-DMT remained a pharmacological curiosity for decades.[2] Toad-venom smoking brought wider public attention in the 1980s, and underground ceremonial use expanded through the 2000s.[3] Multiple clinical programs now investigate formulations for treatment-resistant depression, with Phase 2b data showing 57.7% remission at Day 8.[4]
Subjective effects include rapid ego dissolution, mystical-type experiences, emotional intensification, and somatic overwhelm. The experience is defined by its totality — a near-instantaneous dissolution of self-boundaries into undifferentiated unity, with notably less visual complexity than other classical psychedelics.[5] Intense fear, panic, confusion, and overwhelming disorientation are common unsought effects.[6]
5-MeO-DMT produces no physical dependence and has no established lethal dose in humans.[5] The primary risk is pharmacokinetic: nonlinear dose-response means small dose increases can produce disproportionately intense effects,[7] and MAOI co-administration multiplies exposure several-fold, creating serotonin syndrome risk.[8] Clinical investigation is accelerating, but published human pharmacokinetic parameters remain unavailable as of April 2026.
History[edit]
Discovery
First synthesized by Toshio Hoshino and Kenya Shimodaira in 1936, 5-MeO-DMT predates the better-known synthesis of LSD by seven years.[2] The compound was isolated from the bark of Dictyoloma incanescens in 1959 and subsequently identified in multiple plant genera including Anadenanthera, Phalaris, and Virola. Its presence in the parotoid gland secretions of the Sonoran Desert toad (Incilius alvarius) — first publicized in Albert Most's 1984 pamphlet — brought the compound to broader attention as what researchers called "the first documentation of a hallucinogenic agent from the animal kingdom".[3]
Clinical significance
5-MeO-DMT attracted limited scientific interest for decades after synthesis, with early research focused on its endogenous presence in the mammalian brain and pineal gland.[9] The modern clinical era began in the 2020s: GH Research's vaporized formulation (GH001) progressed through Phase 1 into Phase 2b for treatment-resistant depression,[10] Beckley Psytech developed an intranasal formulation (BPL-003),[11] and the Usona Institute completed a Phase 1 intramuscular study.[12] Phase 2b results showed 57.7% remission at Day 8 and 77.8% at six-month follow-up.[4]
Scheduling
Sweden classified 5-MeO-DMT as a health hazard in October 2004, among the earliest jurisdictions to act.[13] The United States placed it in Schedule I effective January 19, 2011, following 23 law enforcement encounters between 1999 and 2009.[14] China added the compound to its controlled list in October 2015,[13] though it remains unscheduled internationally and legal retreat programs operate in Mexico and other jurisdictions.
The name 5-MeO-DMT follows standard tryptamine shorthand: "5-MeO" denotes the methoxy group at the 5-position of the indole ring, and "DMT" abbreviates dimethyltryptamine. In underground use, the compound is frequently called "the toad" or "toad venom" — a reference to its presence in the secretions of Incilius alvarius, though synthetic material now dominates supply. The toad association has generated conservation concerns, as wild harvesting of I. alvarius populations has intensified alongside growing interest in the compound.
Chemistry[edit]
Structural class
5-MeO-DMT belongs to the substituted tryptamine family, sharing the indolethylamine scaffold common to DMT, psilocin, bufotenine, and the endogenous neurotransmitter serotonin. The 5-methoxy substitution on the indole ring distinguishes it from the 4-substituted psilocybin/psilocin family and the unsubstituted DMT. Metabolic O-demethylation converts 5-MeO-DMT to bufotenine (5-hydroxy-DMT), a pharmacologically significant transformation.[9]
Molecular structure
| Molecular formula | C₁₃H₁₈N₂O |
| Molecular weight | 218.29 g/mol |
The molecule consists of an indole ring with a methoxy group at the 5-position and a dimethylaminoethyl chain at the 3-position. It contains no chirality centers — stereoisomerism is not relevant to the parent compound.
Physical properties
The freebase is a white to off-white crystalline solid with a melting point of 66–70°C.[5][2] For clinical development, a succinate salt (Form A) provides improved stability and water solubility,[15] while the intranasal formulation BPL-003 uses a benzoate salt.[11]
Natural occurrence
5-MeO-DMT occurs in numerous plant species — including Anadenanthera seeds (used in traditional snuffs), Phalaris grasses, and Virola bark resins — and in the parotoid gland secretions of Incilius alvarius.[3] It has also been identified as an endogenous trace amine in the mammalian brain and pineal gland.[9]
Pharmacology[edit]
Mechanism of action
5-MeO-DMT activates serotonin receptors broadly, but its psychedelic effects depend on 5-HT₂A receptor agonism.[1][16] Simultaneous 5-HT₁A activation moderates peak psychedelic intensity while contributing anxiolytic and antidepressant properties.[1] This dual-receptor profile — where one target dampens the output of another — sets 5-MeO-DMT apart from more 5-HT₂A-selective psychedelics like LSD and psilocybin.
A distinguishing feature is the mismatch between binding affinity and functional potency: 5-MeO-DMT binds 5-HT₁A far more tightly in binding assays, yet functions most potently at 5-HT₂A.[17][1] This dissociation means binding data alone do not predict the compound's pharmacological character.
A 2025 cryo-EM study provided the first atomic-resolution image of 5-MeO-DMT bound within the 5-HT₁A receptor, confirming the structural basis for its antidepressant activity.[18] The compound also partitions into cell membranes spontaneously,[19] though the functional significance of this remains unknown. Unlike DMT, 5-MeO-DMT does not bind sigma-1 receptors.[5]
Pharmacokinetics
5-MeO-DMT is broken down through two main routes: rapid deamination by MAO-A (the principal elimination pathway, responsible for the short duration of action) and O-demethylation by CYP2D6, which produces the active metabolite bufotenine.[20][9][7]
Genetic variation in CYP2D6 significantly affects metabolism. The CYP2D6.10 variant — common in East Asian populations — shows 40-fold lower efficiency at producing bufotenine compared to the wild-type enzyme.[8] Individuals who are CYP2D6 poor metabolizers produce less bufotenine, potentially altering the qualitative character of the experience.[21]
No complete human pharmacokinetic data (peak levels, half-life, bioavailability) have been published as of April 2026. Animal studies show peak brain levels within 5–10 minutes and elimination half-lives of 6–19 minutes depending on species.[7]
A critical safety finding is nonlinear pharmacokinetics: at higher doses, blood levels rise disproportionately — 1.5 to 2.7 times higher than dose scaling would predict.[7] Co-administration with the monoamine oxidase inhibitor harmaline increases 5-MeO-DMT exposure 3.6–4.4-fold and bufotenine levels 6–10-fold,[8][22] producing dangerous serotonin syndrome including severe overheating.[23]
Neuroscience[edit]
Where it acts
5-MeO-DMT engages the same core brain systems as other serotonergic psychedelics — primarily 5-HT₂A receptors on cortical pyramidal neurons — but its strong 5-HT₁A co-activation introduces a distinct modulatory signature.[1] No direct neuroimaging of 5-MeO-DMT in humans has been published, but its potent 5-HT₂A agonism predicts disruption of default mode network coherence comparable to or exceeding that of psilocybin and LSD. The concurrent 5-HT₁A activation likely constrains the duration of cortical effects through raphe autoreceptor feedback, potentially explaining why 5-MeO-DMT produces intense ego dissolution with relatively little visual elaboration.
Neuroendocrine data show reductions in salivary cortisol and interleukin-6 following inhalation,[24] suggesting anti-inflammatory and stress-axis modulation, though the relationship to therapeutic effects is unestablished.
Why it matters
The REBUS (Relaxed Beliefs Under Psychedelics) model proposes that psychedelics loosen the brain's high-level predictions, allowing raw sensory and emotional information to reshape mental patterns.[25] 5-MeO-DMT's capacity for rapid, complete ego dissolution aligns with profound disruption of self-model priors — and the brevity of that disruption, followed by rapid reconsolidation, may explain lasting well-being improvements after single sessions.
The compound may also function as a psychoplastogen — promoting structural brain changes independently of the subjective experience. The durability of clinical remission (77.8% at six months)[4] from a 20-minute experience suggests persistent neurobiological changes, though whether these require consciousness of the psychedelic state remains open.
Whether 5-MeO-DMT's ultra-short receptor engagement triggers the same neuroplasticity cascade as longer-acting psychedelics has not been tested — no dendritic complexity or synapse formation studies exist for this compound. The functional significance of its binding at melatonin MT₂ receptors is unknown, and how CYP2D6 genetic variation shapes the neural response remains unexplored.
Subjective Effects[edit]
The 5-MeO-DMT experience is defined less by what the user sees than by what dissolves. Where psilocybin and LSD build elaborate visual worlds, 5-MeO-DMT channels its intensity into the dissolution of self-boundaries — a rapid collapse of identity into undifferentiated awareness, accompanied by somatic overwhelm and emotional enhancement.[5] At lower doses, the experience may involve bodily vibration, spatial distortion, and emotional opening without full ego loss; at common vaporized doses, 75% of participants report complete mystical experiences.[26] Set and setting exert outsized influence on outcome quality — structured, supportive contexts produce significantly higher rates of positive experiences and lower challenging-experience intensity.[27]
Among short-acting psychedelics, the closest comparison is DMT, but the two diverge sharply: DMT is visually complex and often entity-rich, while 5-MeO-DMT tends toward featureless unity states with minimal visual content.[5] The intensity of ego dissolution at common doses exceeds what most users report from other classical psychedelics, a distinction likely driven by the compound's dual 5-HT₂A/5-HT₁A activation profile.[1]
Effect Grid
Common doses produce the characteristic 5-MeO-DMT experience: rapid and intense ego dissolution, powerful emotional amplification across the full valence spectrum (bliss, awe, fear, surrender), and a sense of unity or oceanic boundlessness. Visual effects are present but notably less elaborate than other classical psychedelics — diffuse white light, geometric simplifications, and spatial distortions predominate over complex patterning.
Physically, significant increases in heart rate and blood pressure occur transiently. Nausea, muscle tension, trembling, and vocalization are common. Time distortion is profound — minutes may feel like hours or be entirely absent from awareness. Functional impairment is complete during the peak.
Modeled from the effect's dose-dependence curve — not per-substance measurements.
Proprioceptive distortion · Brightness alteration · Visual haze / noise · Light sensitivity · Color suppression · Touch enhancement · Perspective distortion · Sound sensitivity · Music enhancement · Auditory suppression · Visual acuity suppression · Geometry · Auditory distortion · Depth perception distortion · Touch suppression · Visual drifting · Color alteration · Synesthesia · Visual morphing · Visual breathing · Color enhancement · Tinnitus · Auditory misinterpretation · Tracers · Visual melting · After-images · Environmental patterning · Symmetrical texture repetition · Visual diffraction · Flashbacks · Visual acuity enhancement · Internal hallucinations · Visual processing suppression · Auditory hallucinations · Visual recursion · External hallucinations · Perspective hallucinations · Environmental orbism / cubism · Persisting hallucinations
Color suppression · Touch enhancement · Perspective distortion · Sound sensitivity · Music enhancement · Auditory suppression · Visual acuity suppression · Geometry · Auditory distortion · Depth perception distortion · Touch suppression · Visual drifting · Color alteration · Synesthesia · Visual morphing · Visual breathing · Color enhancement · Tinnitus · Auditory misinterpretation · Tracers · Visual melting · After-images · Environmental patterning · Symmetrical texture repetition · Visual diffraction · Flashbacks · Visual acuity enhancement · Internal hallucinations · Visual processing suppression · Auditory hallucinations · Visual recursion · External hallucinations · Perspective hallucinations · Environmental orbism / cubism · Persisting hallucinations
Pupil dilation · Vibrations / buzzing · Tingling / electric sensations · Stimulation · Body high · Involuntary body movements · Dizziness · Kundalini-like energy · Physical fatigue · Wakefulness · Excessive sweating · Breathing alteration · Heart rate perception changes · Sedation · Tactile euphoria · Bodily heaviness · Bodily pressures · Muscle tension · Nausea · Trembling · Bodily lightness · Muscle relaxation · Restlessness · Respiratory stimulation · Nasal congestion · Pain suppression · Sexual arousal suppression · Yawning · Vomiting · Salivation · Laughter fits · Nystagmus (eye wobbles) · Headache · Dry mouth · Insomnia · Respiratory depression · Watery eyes · Bruxism · Bodily dissociation · Tactile hallucination
Stimulation · Body high · Involuntary body movements · Dizziness · Kundalini-like energy · Physical fatigue · Wakefulness · Excessive sweating · Breathing alteration · Heart rate perception changes · Sedation · Tactile euphoria · Bodily heaviness · Bodily pressures · Muscle tension · Nausea · Trembling · Bodily lightness · Muscle relaxation · Restlessness · Respiratory stimulation · Nasal congestion · Pain suppression · Sexual arousal suppression · Yawning · Vomiting · Salivation · Laughter fits · Nystagmus (eye wobbles) · Headache · Dry mouth · Insomnia · Watery eyes · Bruxism · Bodily dissociation · Tactile hallucination
Memory suppression · Thought disorganization · Analysis suppression · Language suppression · Focus suppression · Memory fragmentation · Openness enhancement · Cognitive euphoria · Introspection enhancement · Novelty enhancement · Cognitive fatigue · Increased nature relatedness · Confusion · Thought connectivity · Cognitive dysphoria · Cognitive flexibility · Conceptual thinking · Thought deceleration · Aesthetic enhancement · Thought acceleration · Creativity enhancement · Pattern recognition enhancement · Thought loops · Multiple thought streams · Synchronicity · Aesthetic suppression · Creativity suppression · Memory replays · Analysis enhancement · Amnesia · Delusions · Delirium
Language suppression · Focus suppression · Memory fragmentation · Openness enhancement · Cognitive euphoria · Introspection enhancement · Novelty enhancement · Cognitive fatigue · Increased nature relatedness · Confusion · Thought connectivity · Cognitive dysphoria · Cognitive flexibility · Conceptual thinking · Thought deceleration · Aesthetic enhancement · Thought acceleration · Creativity enhancement · Pattern recognition enhancement · Thought loops · Multiple thought streams · Synchronicity · Aesthetic suppression · Creativity suppression · Memory replays · Analysis enhancement · Delusions · Delirium
Catharsis · Euphoria · Empathy enhancement · Anxiety suppression · Dysphoria
Dysphoria
Communication suppression · Sociability suppression · Disinhibition · Trust enhancement · Social connection · Compulsive behavior reduction · Flow state · Automaticity · Ego dissolution · Boundary dissolution · Cognitive disconnection · Identity alteration · Telepathic feelings
Social connection · Compulsive behavior reduction · Flow state · Automaticity · Ego dissolution · Boundary dissolution · Cognitive disconnection · Identity alteration · Telepathic feelings
Time cessation
Non-dual awareness · Voidness · Death-rebirth sequence · Near-death experience · Transpersonal visions · Entity contact · Transpersonal memory access
Transpersonal visions · Entity contact · Transpersonal memory access
Lucidity enhancement · Recursive awareness
Timeline
First effects emerge 1-10 minutes after insufflation — nasal burning or discomfort, followed by a gradual shift in headspace and emerging body sensations. Onset is markedly slower than vaporized administration.
Effects build progressively over 5-15 minutes. Body load increases with warmth, nausea, and muscle tension. Emotional sensitivity heightens and ego boundaries begin to soften.
Peak intensity sustained for 10-40 minutes. Ego dissolution, emotional amplification, and mystical-type states emerge with similar quality to vaporized administration but evolve more gradually. Visual effects remain subdued relative to other psychedelics.
A sustained plateau of moderate intensity follows the peak. Emotional processing, introspection, and residual perceptual shifts continue. Body awareness fluctuates between comfortable warmth and mild discomfort.
Gradual return to baseline over 30-60 minutes. Cognitive clarity returns progressively. Emotional sensitivity persists but perceptual distortions fade.
Residual mood changes, emotional openness, and enhanced introspection may persist for 1-4 hours. Nasal congestion or irritation from insufflation may linger. Mild fatigue is common.
Safety[edit]
- Acute toxicity
- Low
- Chronic toxicity
- Negligible
- Withdrawal
- None
- Tolerance buildup
- rapid
- Tolerance reset
- 2 hours
- Physical
- None
- Psychological
- None
- Compulsive redosing
- Negligible
- Dose escalation
- Negligible
- Cross-tol.
- DMT · psilo · LSD
Toxicity
Acute toxicity
No confirmed deaths from 5-MeO-DMT alone appear in national toxicology registries.[5] The human lethal dose is unknown. Animal LD₅₀ values vary enormously across species — from 1 mg/kg in sheep to 278 mg/kg in mice — making cross-species extrapolation unreliable.[5] At supratherapeutic exposures, tryptamine intoxication can produce loss of coordination, tremor, seizures, and respiratory failure.[28]
Heart and circulation
Transient increases in heart rate and blood pressure occur during the acute experience.[10] In the Phase 2b clinical trial, vital signs remained stable and 97.4% of patients were discharge-ready within one hour.[4]
Breathing
5-MeO-DMT can suppress breathing through 5-HT₁A-mediated inhibition of brainstem respiratory neurons, demonstrated in animal models.[29] No respiratory adverse events were reported in published clinical trials, but this effect has not been systematically evaluated at uncontrolled doses.
Overheating
5-MeO-DMT produces elevated body temperature at higher doses. This effect is dramatically worsened by MAOI co-administration: the combination produces synergistic overheating through both 5-HT₁A and 5-HT₂A pathways[23] — a serotonin syndrome mechanism that can be life-threatening.
Nonlinear dose-response
Blood levels rise disproportionately with dose increases due to saturation of metabolic pathways.[7] A dose increase from moderate to high ranges may produce 1.5–2.7× the expected proportional increase in blood levels, making careful titration critical.
Psychological risks
Acute psychological distress scales with dose and is heavily influenced by setting. The most common challenging effects include intense fear, panic, confusion, and overwhelming ego dissolution.[6][5] Historical surveys report psychotic reactions in roughly 10% of cases, though this figure comes from uncontrolled retrospective data and likely reflects dose variability and pre-existing vulnerability.[5]
A minority of users report persistent after-effects including flashbacks, insomnia, and lingering anxiety.[6] Rare cases of HPPD (hallucinogen persisting perception disorder) appear in the retrospective literature.[28] Structured, supportive settings significantly reduce challenging-experience intensity and increase positive outcomes.[27]
Tolerance & Dependence
Tolerance develops rapidly through 5-HT₂A receptor internalization, consistent with the classical psychedelic class.[30] In rodent models, tolerance to psychedelic behavioral effects appears within 24 hours of a single dose.[30] Cross-tolerance with other classical psychedelics is expected based on shared 5-HT₂A mechanism.
5-MeO-DMT produces no physical dependence and has negligible abuse potential. No cases of compulsive use, self-administration studies, or diagnosed use disorder appear in the literature.[6]
Drug Interactions
MAO inhibitors (dangerous)
The most dangerous interaction. Harmaline co-administration increases 5-MeO-DMT blood levels 3.6–4.4-fold and bufotenine levels 6–10-fold,[8][22] producing serotonin toxicity manifesting as dangerous overheating, seizures, and cardiovascular instability.[23][31] This applies to beta-carboline alkaloids (harmaline, harmine, ayahuasca), pharmaceutical MAOIs (phenelzine, tranylcypromine, isocarboxazid), and reversible MAO-A inhibitors (moclobemide).
SSRIs and serotonergic antidepressants
Limited interaction data exist.[32] A 2026 proof-of-concept trial demonstrated that intranasal 5-MeO-DMT can be given alongside SSRIs under medical supervision with acceptable safety.[33] Theoretical risks include combined serotonergic load producing serotonin syndrome and chronic SSRI use reducing psychedelic response through 5-HT₂A downregulation.
Tramadol
Tramadol has weak MAOI activity and inhibits serotonin reuptake. Combined serotonergic load with 5-MeO-DMT could precipitate serotonin syndrome. No specific interaction data exist.inferred
Stimulants (cocaine)
Cocaine raises monoamine levels and increases cardiovascular stress. Combined with 5-MeO-DMT's autonomic effects, cardiovascular risk is plausible. No interaction data exist.inferred
Lithium
Lithium combined with serotonergic psychedelics is associated with seizure risk. No 5-MeO-DMT-specific data exist, but the interaction is flagged based on class evidence.inferred
CYP2D6 inhibitors
Drugs that inhibit CYP2D6 (fluoxetine, paroxetine, bupropion, quinidine) could reduce bufotenine formation and alter the pharmacological profile. This interaction is mechanistically predicted but not experimentally confirmed.[31]
Contraindications
Concurrent MAOI use is an absolute contraindication outside controlled clinical settings. The quantified 3.6–4.4-fold exposure increase and documented serotonin toxicity risk[8][23] place this combination in the highest-risk category.
Personal or family history of psychotic disorders is a relative contraindication consistent with all classical psychedelics. The speed and intensity of ego dissolution may present elevated risk for psychotic decompensation.
Heart conditions warrant caution given documented increases in heart rate and blood pressure.[10]
Breathing difficulties are a theoretical contraindication based on demonstrated respiratory suppression in animal models.[29]
Pregnancy and breastfeeding are contraindicated in the absence of reproductive safety data.
Harm Reduction[edit]
Forms & Identification
The structured data module above shows reagent results, physical forms, and common substitution risks. 5-MeO-DMT circulates as freebase powder (for vaporization), crystalline material, and occasionally as dried toad secretion — each form carrying different dosing precision challenges.
Reagent testing confirms the presence of an indole-containing tryptamine but cannot distinguish 5-MeO-DMT from closely related compounds like DMT or bufotenine. Quantitative testing (such as HPLC) is the only reliable method for confirming identity and purity. For toad-derived material, the presence of cardiac steroids (bufotoxins) alongside 5-MeO-DMT poses additional toxicity risk that reagent kits cannot detect — synthetic material eliminates this concern entirely.
Guidelines
- Test material before use. Reagent testing confirms tryptamine class; quantitative analysis confirms identity and purity. Do not rely on appearance alone.
- Use a precision milligram scale. Nonlinear pharmacokinetics mean small dose errors produce disproportionate effects.[7] Eyeballing doses is dangerous with this compound.
- Start with a low dose. CYP2D6 genetic variation affects metabolism significantly[21] — individual sensitivity is unpredictable without prior experience.
- Have an experienced sitter present. The onset is too rapid and the ego dissolution too complete for unsupervised first experiences.
- Fast for at least 4 hours beforehand. Nausea and vomiting can occur; aspiration risk increases when combined with loss of motor control.
- Prepare the physical space. Remove sharp objects and hard edges from the immediate area. Use a padded surface. The person may move involuntarily during the experience.
- Allow full recovery time before standing. Disorientation can persist for 15–30 minutes after the acute experience resolves. Do not drive or operate equipment for several hours.
Set & Setting
The quality of a 5-MeO-DMT experience is unusually sensitive to context. Structured, supportive environments produce significantly higher rates of complete mystical experiences (83% vs 54%) and substantially lower challenging-experience scores.[27] The speed of onset — full effects within seconds when vaporized — means there is no gradual entry period to adjust.
A safe, comfortable physical space and a trusted, experienced sitter are strongly recommended. The sitter should be prepared for intense physical responses (involuntary movement, vocalization) and should understand that verbal reassurance may not reach the person during peak dissolution.
Aftercare & integration. The 5-MeO-DMT experience — particularly at ego-dissolving doses — can be profoundly disorienting even when subjectively positive. The brevity of the acute phase does not reflect the psychological weight of the experience.
Allow the remainder of the day for quiet recovery. Journaling within the first few hours captures impressions that fade quickly. Avoid making major life decisions in the days immediately following — the experience frequently produces a sense of clarity that benefits from reflection before action.
Integration — the process of making meaning from the experience — may benefit from professional support, particularly if the experience was distressing or surfaced difficult emotional material. Persistent anxiety, intrusive memories, or sleep disturbances lasting more than two weeks warrant professional evaluation.
Recovery & Support
5-MeO-DMT does not produce physical dependence, and compulsive use patterns are not documented in the literature. However, repeated ceremonial or retreat use — sometimes driven by a desire to recapture the intensity of the experience — can indicate problematic patterns that benefit from honest self-assessment.
If psychedelic use is causing distress, interfering with daily functioning, or being used to avoid addressing underlying issues, professional support is recommended. The Fireside Project (62-FIRESIDE) offers a psychedelic peer support line, and integration therapists can help process difficult or recurring experiences.
Recovery resources, crisis lines, and support pathways → View all
Emergency Response
Recognizing an emergency:
Most 5-MeO-DMT experiences involve intense but transient distress that resolves without intervention. Seek emergency help if any of the following occur:
- Seizure or convulsions
- Breathing stops or becomes very slow
- Loss of consciousness that persists after the acute phase should have ended
- Rigid muscles with high body temperature (signs of serotonin syndrome — especially if MAOIs were involved)
- Self-harm behavior or attempts to flee into unsafe environments
Immediate steps:
- 1. Call emergency services if any of the above signs are present.
- 2. Place the person in the recovery position if unconscious but breathing.
- 3. Do not restrain the person unless they are in immediate physical danger.
- 4. Monitor breathing continuously. If breathing stops and you are trained, begin rescue breathing.
- 5. Keep the environment calm and quiet. Reduce stimulation.
What to tell the dispatcher:
State that the person has used a psychedelic tryptamine, the approximate amount and time of use, and current symptoms. Good Samaritan laws in many jurisdictions protect callers who report drug-related emergencies.
Legal Status[edit]
5-MeO-DMT is not listed in the United Nations Convention on Psychotropic Substances, meaning countries without domestic legislation have no international obligation to control it.[13] Legal retreat programs operate in Mexico and other jurisdictions where no domestic scheduling exists. Several countries have enacted independent controls, with the United States and United Kingdom imposing the strictest classifications.
| Jurisdiction | Classification | Key provisions |
|---|---|---|
| United States | Schedule I (Controlled Substances Act) | Effective January 19, 2011; includes salts, isomers, and salts of isomers[14] |
| United Kingdom | Class A (Misuse of Drugs Act 1971) | Illegal to possess, supply, or manufacture without license[13] |
| Canada | Not explicitly scheduled | Not listed under the Controlled Drugs and Substances Act; analog provisions may apply[13] |
| Australia | Controlled substance | Illegal to use, possess, or supply[13] |
| Sweden | Health hazard classification | Controlled since October 2004[13] |
| China | Controlled substance | Added to controlled list October 2015[13] |
| Mexico | Not controlled | No domestic scheduling; legal retreat programs operatecitation needed |
Clinical trial programs in the United States and Europe operate under investigational exemptions. Should any formulation receive regulatory approval, scheduling classifications would require review — a pathway being established by psilocybin and MDMA regulatory processes.
references
- [1]
- [2]
- [3] ^abcWeil AT, Davis W (1994) Bufo alvarius: a potent hallucinogen of animal origin — Journal of Ethnopharmacology PMID:8170151
- [4]
- [5]
- [6] ^abcdDavis AK, Barsuglia JP, Lancelotta R, Grant RM, Renn E (2018) The epidemiology of 5-methoxy-N,N-dimethyltryptamine (5-MeO-DMT) use: Benefits, consequences, patterns of use, subjective effects, and reasons for consumption — Journal of Psychopharmacology doi:10.1177/0269881118769063